Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Express Scripts
Covington
US Department of Justice
US Army
AstraZeneca
Mallinckrodt
Boehringer Ingelheim

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XALATAN

« Back to Dashboard

Clinical Trials for Xalatan

Trial ID Title Status Sponsor Phase Summary
NCT00140062 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed Pfizer Phase 4 The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
NCT00143429 Corneal Versus Conjunctival Delivery Using a Delivery Device Withdrawn Pfizer Phase 2 Compare the antihypertensive efficacy of three methods for installing Xalatan
NCT00159653 A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma Completed Pfizer Phase 3 To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
NCT00187577 Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata Completed University of California, San Francisco N/A This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day.
NCT00224289 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed Pfizer Phase 4 Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We are going to study the effectiveness of Latanoprost in people of different ages, to see if it changes based on the age of the patient.
NCT00224289 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed Yale University Phase 4 Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We are going to study the effectiveness of Latanoprost in people of different ages, to see if it changes based on the age of the patient.
NCT00273429 Cosopt Versus Xalatan Completed Pharmaceutical Research Network Phase 4 To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Xalatan

Condition Name

Condition Name for Xalatan
Intervention Trials
Ocular Hypertension 42
Glaucoma 21
Open-Angle Glaucoma 18
Glaucoma, Open-Angle 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xalatan
Intervention Trials
Glaucoma 56
Ocular Hypertension 45
Hypertension 39
Glaucoma, Open-Angle 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xalatan

Trials by Country

Trials by Country for Xalatan
Location Trials
United States 113
Canada 14
Japan 13
Greece 3
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xalatan
Location Trials
Texas 10
Florida 7
California 6
Pennsylvania 5
New Jersey 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xalatan

Clinical Trial Phase

Clinical Trial Phase for Xalatan
Clinical Trial Phase Trials
Phase 4 30
Phase 3 14
Phase 2 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xalatan
Clinical Trial Phase Trials
Completed 49
Unknown status 6
Recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xalatan

Sponsor Name

Sponsor Name for Xalatan
Sponsor Trials
Pfizer 17
Alcon Research 16
Allergan 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xalatan
Sponsor Trials
Industry 50
Other 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fish and Richardson
Fuji
Moodys
Teva
McKesson
Cantor Fitzgerald
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.